Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.